```markdown
---
application_number: 212501Orig1s000
applicant:
  name: Ingenus Pharmaceuticals, LLC
  agent: Ricon Pharma, LLC
  contact_name: Mukteeshwar Gande
  contact_title: Chief Scientific Officer
  address: 100 Ford Road, Suite #9, Denville, NJ 07834
drug:
  name: Cyclophosphamide Injection
  doses:
    - 500 mg/2.5 mL
    - 1 g/5 mL
submission:
  original_submission_date: 2018-09-27
  complete_response_amendment_date: 2019-07-24
  additional_amendment_date: 2019-12-26
action:
  letter_type: Complete Response
  issued_dates:
    - 2019-07-18
    - 2020-01-14
review_team:
  deputy_director: Amna Ibrahim, MD
  division: Division of Oncology 1
  office: Office of Oncologic Diseases
  center: Center for Drug Evaluation and Research
regulatory_contact:
  name: Fatima Rizvi, PharmD
  title: Regulatory Project Manager
  phone: (240) 402-7426
  email: Fatima.Rizvi@fda.hhs.gov
enclosures:
  - Labeling
  - Carton/Container Labeling
---

## Critical Data

| Field                         | Value                                                                 |
|------------------------------|-----------------------------------------------------------------------|
| Application Number           | 212501Orig1s000                                                       |
| Drug Name                    | Cyclophosphamide Injection                                            |
| Dosage Forms                 | 500 mg/2.5 mL and 1 g/5 mL                                            |
| Submission Type              | NDA under section 505(b)(2)                                           |
| Applicant                    | Ingenus Pharmaceuticals, LLC                                          |
| Agent                        | Ricon Pharma, LLC                                                     |
| Contact                      | Mukteeshwar Gande, Chief Scientific Officer                           |
| FDA Review Division          | Division of Oncology 1                                               |
| FDA Office                   | Office of Oncologic Diseases                                          |
| Review Center                | Center for Drug Evaluation and Research                               |
| Action Letters Issued        | July 18, 2019 and January 14, 2020                                    |
| Regulatory Contact           | Fatima Rizvi, PharmD (Fatima.Rizvi@fda.hhs.gov, (240) 402-7426)      |
| Enclosures                   | Labeling, Carton/Container Labeling                                   |

---

# CENTER FOR DRUG EVALUATION AND RESEARCH

## APPLICATION NUMBER: 212501Orig1s000

## OTHER ACTION LETTERS

---

# NDA 212501  
## COMPLETE RESPONSE  

Ingenus Pharmaceuticals, LLC  
c/o Ricon Pharma, LLC  
Attention: Mukteeshwar Gande, Chief Scientific Officer  
100 Ford Road, Suite #9  
Denville, NJ 07834  

Dear Dr. Gande:

Please refer to your new drug application (NDA) dated September 27, 2018, received September 27, 2018, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Cyclophosphamide Injection, 500 mg/2.5 mL and 1 g/5 mL.

We acknowledge receipt of your amendment dated July 24, 2019, which constituted a complete response to our July 18, 2019, action letter.

We also acknowledge receipt of your amendment dated December 26, 2019, which was not reviewed for this action. You may incorporate applicable sections of the amendment by specific reference as part of your response to the deficiencies cited in this letter.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

---

## FACILITY INSPECTIONS

During a recent inspection of the manufacturing facility for this application, our field investigator observed objectionable conditions at the facility and conveyed that information to the representative of the facility at the close of the inspection. Satisfactory resolution of the observations is required before this application may be approved.

> In response to this deficiency, provide a statement from the facility stating that all issues have been resolved. Do not submit actual inspectional correspondence to this application.

---

## PRESCRIBING INFORMATION

Your proposed Prescribing Information (PI) must conform to the content and format regulations found at 21 CFR 201.56(a) and (d) and 201.57. As you develop your proposed PI, we encourage you to review the labeling review resources on the PLR Requirements for Prescribing Information and Pregnancy and Lactation Labeling Final Rule websites, which include:

- The Final Rule (Physician Labeling Rule) on the content and format of the PI for human drug and biological products
- The Final Rule (Pregnancy and Lactation Labeling Rule) on the content and format of information in the PI on pregnancy, lactation, and females and males of reproductive potential
- Regulations and related guidance documents
- A sample tool illustrating the format for Highlights and Contents
- The Selected Requirements for Prescribing Information (SRPI) âˆ’ a checklist of important format items from labeling regulations and guidances
- FDAâ€™s established pharmacologic class (EPC) text phrases for inclusion in the Highlights Indications and Usage heading

> Submit draft labeling that addresses our proposed revisions in the attached labeling.

Prior to resubmitting the labeling:

- Use the SRPI checklist to correct any formatting errors.
- Ensure conformance with the format items in regulations and guidances.
- Submit updated content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format.

To facilitate review of your submission:

- Provide a highlighted or marked-up copy that shows all changes.
- Submit a clean Word version.
- The marked-up copy should include annotations that support any proposed changes.

---

## CARTON AND CONTAINER LABELING

Submit draft carton and container labeling revised, as attached, based on our proposed revisions.

---

## SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.
2. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:
    - Present new safety data using the same format as in the original submission.
    - Present tabulations of the new safety data combined with the original application data.
    - Include tables comparing frequencies of adverse events in the original application with the retabulated frequencies.
    - For other indications, provide separate tables for adverse event frequencies in clinical trials.
3. Present a retabulation of premature trial discontinuation reasons by incorporating drop-outs from newly completed trials and describing any new trends or patterns.
4. Provide case report forms and narrative summaries for patients who died or discontinued due to an adverse event. Also include summaries of serious adverse events.
5. Describe information suggesting a substantial change in the incidence of common, but less serious, adverse events.
6. Provide updated exposure information (e.g., number of subjects, person time).
7. Provide a summary of worldwide experience on the drug's safety and updated estimates of international usage.
8. Provide English translations of current approved foreign labeling not previously submitted.

---

## OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If no action is taken, we may consider your lack of response a request to withdraw the application under 21 CFR 314.65. You may request an extension of time to resubmit the application.

A resubmission:

- Must fully address all the deficiencies listed in this letter
- Should be clearly marked with **"RESUBMISSION"** in large font, bolded type at the beginning of the cover letter
- The cover letter should clearly state that you consider the resubmission a complete response

> Partial responses will not be processed or restart the review cycle.

You may request a meeting or teleconference to discuss the steps needed before we can approve the application. Submit your request as described in the draft guidance for industry: _Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products_.

> The drug product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, contact:  
Fatima Rizvi, PharmD  
Regulatory Project Manager  
ðŸ“ž (240) 402-7426  
ðŸ“§ Fatima.Rizvi@fda.hhs.gov

---

Sincerely,  
Amna Ibrahim, MD  
Deputy Director  
Division of Oncology 1  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research  

---

### ENCLOSURES:

- Labeling  
- Carton/Container Labeling  

> 21 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS)

---

/s/  
**AMNA IBRAHIM**  
01/14/2020 11:04:24 AM  

---

# NDA 212501  
## COMPLETE RESPONSE  

Ricon Pharma, LLC  
Agent for Ingenus Pharmaceuticals, LLC  
Attention: Mukteeshwar Gande, Chief Scientific Officer  
100 Ford Road, Suite #9  
Denville, NJ 07834  

Dear Mr. Gande:

Please refer to your new drug application (NDA) dated September 27, 2018, submitted under section 505(b)(2) for Cyclophosphamide Injection.

We have completed our review and cannot approve this application in its current form. Deficiencies are described below along with recommended actions.

---

## FACILITY INSPECTIONS

Our field investigator has conveyed deficiencies to the representative of the manufacturing facility. These must be satisfactorily resolved before the application can be approved.

---

## PRESCRIBING INFORMATION

Your PI must comply with regulations [21 CFR 201.56(a), (d), and 201.57]. Refer to:

- [Physician Labeling Rule (PLR)](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)
- [Pregnancy and Lactation Labeling Rule (PLLR)](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)

Resources include rules, regulations, templates, checklists, and example text for inclusion.

> Submit revised labeling based on attached revisions.

Submit:

- SRPI checklist with corrections
- Updated labeling content in [SPL format](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)
- A marked-up copy showing changes with annotations
- A clean Word copy

---

## CARTON AND CONTAINER LABELING

Submit revised carton and container labeling based on attached revisions.

---

## OTHER

You must resubmit or take other action under 21 CFR 314.110 within one year. If not, we may consider this a request to withdraw the application under 21 CFR 314.65. Extension requests may be submitted.

> Resubmissions must fully address deficiencies and be marked **"RESUBMISSION"** in bold font in the cover letter.

Partial responses will not reset the review cycle.

You may request a meeting or teleconference if needed. Use the draft guidance: _Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products_.

> This drug product may not be marketed until you receive written FDA approval.

Contact:  
Fatima Rizvi, PharmD  
Regulatory Project Manager  
ðŸ“ž (240) 402-7426  
ðŸ“§ Fatima.Rizvi@fda.hhs.gov

---

Sincerely,  
Amna Ibrahim, MD  
Deputy Director  
Division of Oncology Products 1  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research  

---

### ENCLOSURES:

- Labeling  
- Carton/Container Labeling  

> 21 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS)

---

/s/  
**AMNA IBRAHIM**  
07/18/2019 12:36:44 PM
```